Clinical Trial

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-08-25; most recent amendment 2026-02-15.
Status change: Not Yet Recruiting → Recruiting 2025-10-29
Trial Details
NCT Number NCT07145255
Lead Sponsor MBrace Therapeutics
Conditions Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
Enrollment 150 participants
Start Date 2025-09-03
Primary Completion 2029-09-30 (estimated)
Study Completion 2029-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-17